Forensic Toxicology

, Volume 31, Issue 1, pp 70–75 | Cite as

Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity

  • Satoshi Yamaori
  • Mika Kushihara
  • Kyoko Koeda
  • Ikuo Yamamoto
  • Kazuhito Watanabe
Original Article

Abstract

We recently reported that Δ9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive constituent in marijuana, potently inhibits the catalytic activity of cytochrome P450 (CYP) 2C9.1, a wild-type variant. However, effects of CYP2C9 genetic polymorphisms on the inhibitory potency of Δ9-THC have not been investigated. In this study, in vitro inhibitory effects of Δ9-THC on catalytic activities of two major allelic variants, CYP2C9.2 and CYP2C9.3, were examined with the recombinant enzymes. Δ9-THC inhibited S-warfarin 7-hydroxylation, diclofenac 4′-hydroxylation, and tolbutamide 4-hydroxylation by CYP2C9.2 and CYP2C9.3 in a concentration-dependent manner. The IC50 values for the catalytic activities toward S-warfarin, diclofenac, and tolbutamide were 2.39, 1.04, and 1.12 μM, respectively, for CYP2C9.2, and 2.91, 1.38, and 1.09 μM, respectively, for CYP2C9.3. The inhibitory potencies against these mutant variants were similar to those against the wild-type variant. In contrast, Δ9-THC inhibited 7-methoxy-4-(trifluoromethyl)coumarin O-demethylase activity of CYP2C9.1, CYP2C9.2, and CYP2C9.3 to various extents, showing the IC50 values of 1.02, 4.20 and >10 μM, respectively. Our recent study showed that a preincubation of Δ9-THC in the presence of NADPH decreased the inhibitory effect on CYP2C9.1 activity. Then the effect of preincubation on Δ9-THC-mediated inhibition of S-warfarin 7-hydroxylation was investigated with CYP2C9.2 and CYP2C9.3. The preincubation of Δ9-THC with CYP2C9.2 attenuated the inhibitory effect of the phytocannabinoid, whereas preincubation with CYP2C9.3 did not. These results indicate that the inhibitory effects of Δ9-THC on CYP2C9 variants depend on the substrates used and the preincubation time.

Keywords

Marijuana Cannabinoid Δ9-Tetrahydrocannabinol CYP2C9 variants Inhibition Polymorphism 

References

  1. 1.
    Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374:1383–1391PubMedCrossRefGoogle Scholar
  2. 2.
    Wu LT, Schlenger WE, Galvin DM (2006) Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend 84:102–113PubMedCrossRefGoogle Scholar
  3. 3.
    Grov C, Kelly BC, Parsons JT (2009) Polydrug use among club-going young adults recruited through time-space sampling. Subst Use Misuse 44:848–864PubMedCrossRefGoogle Scholar
  4. 4.
    Okoli CT, Richardson CG, Ratner PA, Johnson JL (2008) Adolescents’ self-defined tobacco use status, marijuana use, and tobacco dependence. Addict Behav 33:1491–1499PubMedCrossRefGoogle Scholar
  5. 5.
    Ream GL, Benoit E, Johnson BD, Dunlap E (2008) Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend 95:199–208PubMedCrossRefGoogle Scholar
  6. 6.
    Midanik LT, Tam TW, Weisner C (2007) Concurrent and simultaneous drug and alcohol use: results of the 2000 National Alcohol Survey. Drug Alcohol Depend 90:72–80PubMedCrossRefGoogle Scholar
  7. 7.
    Lemberger L, Tamarkin NR, Axelrod J, Kopin IJ (1971) Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 173:72–74PubMedCrossRefGoogle Scholar
  8. 8.
    Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM (1978) Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther 24:405–410PubMedGoogle Scholar
  9. 9.
    Benowitz NL, Jones RT (1981) Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21:214S–223SPubMedGoogle Scholar
  10. 10.
    Wilens TE, Biederman J, Spencer TJ (1997) Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 36:45–48PubMedCrossRefGoogle Scholar
  11. 11.
    Yamreudeewong W, Wong HK, Brausch LM, Pulley KR (2009) Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 43:1347–1353PubMedCrossRefGoogle Scholar
  12. 12.
    Bornheim LM, Lasker JM, Raucy JL (1992) Human hepatic microsomal metabolism of Δ1-tetrahydrocannabinol. Drug Metab Dispos 20:241–246PubMedGoogle Scholar
  13. 13.
    Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H (1995) Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 18:1138–1141PubMedCrossRefGoogle Scholar
  14. 14.
    Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I (2007) Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 80:1415–1419PubMedCrossRefGoogle Scholar
  15. 15.
    Watanabe K, Fujinami M, Yamaori S, Yamamoto I (2011) Possible involvement of Cyp3a enzymes in the metabolism of tetrahydrocannabinols by mouse brain microsomes. Forensic Toxicol 29:56–60CrossRefGoogle Scholar
  16. 16.
    Bland TM, Haining RL, Tracy TS, Callery PS (2005) CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 70:1096–1103PubMedCrossRefGoogle Scholar
  17. 17.
    Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmöller J (2009) Interindividual variation in the pharmacokinetics of Δ9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 85:273–276PubMedCrossRefGoogle Scholar
  18. 18.
    Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K (2012) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet 27:294–300PubMedGoogle Scholar
  19. 19.
    Aramaki H, Tomiyasu N, Yoshimura H, Tsukamoto H (1968) Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull 16:822–826PubMedCrossRefGoogle Scholar
  20. 20.
    Watanabe K, Motoya E, Matsuzawa N, Funahashi T, Kimura T, Matsunaga T, Arizono K, Yamamoto I (2005) Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206:471–478PubMedCrossRefGoogle Scholar
  21. 21.
    Yamaori S, Kushihara M, Yamamoto I, Watanabe K (2010) Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691–1698PubMedCrossRefGoogle Scholar
  22. 22.
    Yamaori S, Maeda C, Yamamoto I, Watanabe K (2011) Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 29:117–124CrossRefGoogle Scholar
  23. 23.
    Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K (2011) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88:730–736PubMedCrossRefGoogle Scholar
  24. 24.
    Yamaori S, Okamoto Y, Yamamoto I, Watanabe K (2011) Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39:2049–2056PubMedCrossRefGoogle Scholar
  25. 25.
    Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966–1975PubMedCrossRefGoogle Scholar
  26. 26.
    Suarez-Kurtz G (2005) Pharmacogenomics in admixed populations. Trends Pharmacol Sci 26:196–201PubMedCrossRefGoogle Scholar
  27. 27.
    Wang B, Wang J, Huang SQ, Su HH, Zhou SF (2009) Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 10:781–834PubMedCrossRefGoogle Scholar
  28. 28.
    Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203–210PubMedCrossRefGoogle Scholar
  29. 29.
    Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12:251–263PubMedCrossRefGoogle Scholar
  30. 30.
    Zi J, Liu D, Ma P, Huang H, Zhu J, Wei D, Yang J, Chen C (2010) Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug–drug interactions. Drug Metab Pharmacokinet 25:343–350PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Association of Forensic Toxicology and Springer 2012

Authors and Affiliations

  • Satoshi Yamaori
    • 1
  • Mika Kushihara
    • 1
  • Kyoko Koeda
    • 1
  • Ikuo Yamamoto
    • 3
  • Kazuhito Watanabe
    • 1
    • 2
  1. 1.Department of Hygienic Chemistry, Faculty of Pharmaceutical SciencesHokuriku UniversityKanazawaJapan
  2. 2.Organization for Frontier Research in Preventive Pharmaceutical SciencesHokuriku UniversityKanazawaJapan
  3. 3.Department of Hygienic Chemistry, School of Pharmaceutical SciencesKyushu University of Health and WelfareNobeokaJapan

Personalised recommendations